BioDelivery Sciences Announces Five Medical Abstracts Accepted at PAINWeek® 2019 National Conference on Pain Management
August 28, 2019 07:45 ET
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., Aug. 28, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with chronic...
SPR Therapeutics’ SPRINT Peripheral Nerve Stimulation System Significantly Reduces Opioid Use in Patients with Low Back Pain, Interim Data Show
August 21, 2019 08:30 ET
|
SPR Therapeutics, Inc.
CLEVELAND, Ohio and KISSIMMEE, Florida, Aug. 21, 2019 (GLOBE NEWSWIRE) -- SPR Therapeutics, Inc., a leader in neurostimulation technology for pain management, presented interim results today on the...
Abt Expands Opioid Quality Improvement Collaborative, Aims To Improve Chronic Pain Care
August 14, 2019 11:06 ET
|
Abt Associates
Rockville, Md., Aug. 14, 2019 (GLOBE NEWSWIRE) -- Abt Associates has expanded the Opioid Quality Improvement (QI) Collaborative launched in March 2018 to a second cohort of healthcare systems....
BioDelivery Sciences Reports Strong Second Quarter 2019 Results and Raises Net Sales Expectations
August 08, 2019 16:05 ET
|
BioDelivery Sciences International, Inc.
BELBUCA® Net Sales Increased 147% versus Prior Year to All-Time High of $24.1 MillionRaises Full-Year BELBUCA Net Sales Expectations to $90 - $93 MillionRaises Full-Year Total Company Net Sales...
BioDelivery Sciences Announces Further Improved Insurance Coverage for BELBUCA®
July 09, 2019 08:00 ET
|
BioDelivery Sciences International, Inc.
Regional Commercial Plans Improved Access for More Than 6 Million Lives During 2Q More Than 90% of Commercial Lives Now Have Access to BELBUCA in the U.S. RALEIGH, N.C., July 09, 2019 (GLOBE...
BioDelivery Sciences Expands Upon Report from Pain Management Task Force
June 24, 2019 08:00 ET
|
BioDelivery Sciences International, Inc.
Company’s Activities Support Buprenorphine Recommendations Including: Primary Use of Buprenorphine in Chronic Pain when Clinically IndicatedHaving Payers Provide Coverage and Reimbursement for...
BioDelivery Sciences Named to the Russell 3000® Index
June 20, 2019 08:00 ET
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., June 20, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is set to be added to the broad-market Russell 3000® Index as well as the Russell 2000® Index...
BioElectronics Announces Publication of Study Verifying the Effectiveness of Its ActiPatch Medical Device on Chronic Pain
June 03, 2019 09:31 ET
|
BioElectronics Corporation
FREDERICK, MD, June 03, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioElectronics Corporation (OTC PINK: BIEL) www.bielcorp.com, the maker of non-invasive electroceutical devices, is pleased to...
BioDelivery Sciences Announces Upcoming Investor Conference Presentations
May 29, 2019 16:10 ET
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., May 29, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients...
BioDelivery Sciences Strengthens Financial Position with Debt Refinancing
May 28, 2019 16:10 ET
|
BioDelivery Sciences International, Inc.
New Agreement is Cash Flow Accretive, Lowers Cost of Capital and Extends Debt Maturity Reduces Annual Interest Costs by Approximately $1.5 million Increases Flexibility to Continue Growth Trajectory...